SUBSTITUTED THIOPYRANO[2,3,4-C,D]INDOLES AS POTENT, SELECTIVE, AND ORALLY-ACTIVE INHIBITORS OF 5-LIPOXYGENASE - SYNTHESIS AND BIOLOGICAL EVALUATION OF L-691,816

被引:40
作者
HUTCHINSON, JH [1 ]
RIENDEAU, D [1 ]
BRIDEAU, C [1 ]
CHAN, C [1 ]
DELORME, D [1 ]
DENIS, D [1 ]
FALGUEYRET, JP [1 ]
FORTIN, R [1 ]
GUAY, J [1 ]
HAMEL, P [1 ]
JONES, TR [1 ]
MACDONALD, D [1 ]
MCFARLANE, CS [1 ]
PIECHUTA, H [1 ]
SCHEIGETZ, J [1 ]
TAGARI, P [1 ]
THERIEN, M [1 ]
GIRARD, Y [1 ]
机构
[1] MERCK FROSST CTR THERAPEUT RES,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA
关键词
D O I
10.1021/jm00071a008
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Thiopyrano[2,3,4-c,d]indoles are a new class of 5-lipoxygenase (5-LO) inhibitors. SAR studies have demonstrated that the thiopyran ring, the 5-phenylpyridine substituent, and an acidic functional group on a four-carbon C-2 side chain are all required for optimal inhibitor potency. In contrast, the indolic nitrogen may be substituted with a variety of lipophilic groups. As a result of the SAR investigation, 44 (L-691,816; 5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole) has been identified as a potent inhibitor of the 5-LO reaction both in vitro and in a range of in vivo models. Compound 44 inhibits 5-HPETE production by both rat and human 5-LO and LTB4 synthesis in human PMN leukocytes (IC50s 16,75, and 10 nM, respectively). The mechanism of inhibition of 5-LO activity by compound 44 appears to involve the formation of a reversible deadend complex with the enzyme and does not involve reduction of the nonheme iron of 5-LO. Compound 44 is highly selective for 5-LO when compared to the inhibition of human FLAP, porcine 12-LO, and also ram seminal vesicle cyclooxygenase. In addition, 44 is orally active in a rat pleurisy model (inhibition of LTB4, ED50 = 1.9 mg/kg; 8 h pretreatment) as well as in the hyperreactive rat model of antigen-induced dyspnea (ED50 = 0.1 mg/kg;2-h pretreatment). Excellent functional activity was also observed in both the conscious allergic monkey and sheep models of asthma. In the latter case, the functional activity observed correlated with the inhibition of urinary LTE4 excretion.
引用
收藏
页码:2771 / 2787
页数:17
相关论文
共 43 条
[1]  
ABRAHAM WM, 1991, EUR J PHARMACOL, V217, P119
[2]   COMPARATIVE EFFECTS OF INHALED LEUKOTRIENE-C4, LEUKOTRIENE-D4, AND HISTAMINE IN NORMAL HUMAN-SUBJECTS [J].
BARNES, NC ;
PIPER, PJ ;
COSTELLO, JF .
THORAX, 1984, 39 (07) :500-504
[3]  
BIGI F, 1981, SYNTHESIS-STUTTGART, P310
[4]   UBER ACETYLMERCAPTOMETHYL-RHODANID, -SENFOL UND-CYANID [J].
BOEHME, H ;
DICK, A .
ARCHIV DER PHARMAZIE UND BERICHTE DER DEUTSCHEN PHARMAZEUTISCHEN GESSELSCHAFT, 1961, 294 (08) :475-&
[5]   PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR [J].
BRIDEAU, C ;
CHAN, C ;
CHARLESON, S ;
DENIS, D ;
EVANS, JF ;
FORDHUTCHINSON, AW ;
FORTIN, R ;
GILLARD, JW ;
GUAY, J ;
GUEVREMONT, D ;
HUTCHINSON, JH ;
JONES, TR ;
LEGER, S ;
MANCINI, JA ;
MCFARLANE, CS ;
PICKETT, C ;
PIECHUTA, H ;
PRASIT, P ;
RIENDEAU, D ;
ROUZER, CA ;
TAGARI, P ;
VICKERS, PJ ;
YOUNG, RN ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) :799-807
[6]  
CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929
[7]  
CHARLESON S, 1992, MOL PHARMACOL, V41, P873
[8]   RATIONALLY DESIGNED, POTENT COMPETITIVE INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS [J].
COREY, EJ ;
CASHMAN, JR ;
KANTNER, SS ;
WRIGHT, SW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (05) :1503-1504
[9]  
DENIS D, 1991, J BIOL CHEM, V266, P5072
[10]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284